in early 2016. Europe and Emerging market are ready to have a huge recovery in 2016 based on aggressive Q/E program just like US.did the last 3 years.
Sentiment: Strong Buy
Will FCX bring back the dividend in 2016 and recover please?
thank you very much, planet. That is total of 36 cents which will help a great deal.
It is clear the CEO is a brilliant scientist instead of a businessman.
Array Reports Positive Results from Its Phase 3 Study
XBI, IBB Lead Biotechnology Sector Gains
(Continued from Prior Part)
Small-caps were the best among biotechnology stocks
Small-cap stocks fared better than mid- and large-cap stocks for the week ended December 18, 2015.
The small-cap stocks of the iShares Nasdaq Biotechnology ETF (IBB) returned 6.0%, the small-caps of the SPDR S&P Biotech ETF (XBI) returned 6.8%, the small-caps of the iShares US Medical Devices ETF (IHI) returned 3.1%, and the small-caps of the iShares US Healthcare Providers ETF (IHF) returned 0.6% for the week ended December 18, 2015.
The above graph reflects the performances of the small-cap stocks of the different biotechnology ETFs on a week-over-week basis. Some of the small-caps that outperformed the market were Five Prime Therapeutics (FPRX), Geron (GERN), and Sequenom (SQNM). They gave returns of 14.3%, 13.9%, and 16.6%, respectively.
Array reports positive results from its Phase 3 study – stock spirals up
Array BioPharma (ARRY) rose 14.5% for the week ended December 18, 2015. The stock gained on positive results from its Phase 3 study of its drug binimetinib.
As per its press release, ARRY “reported top-line results from the ongoing Phase 3 clinical trial of binimetinib in patients with advanced NRAS-mutant melanoma, known as the NEMO trial. The study met its primary endpoint of improving progression-free survival (or PFS) compared with dacarbazine treatment. The median PFS on the binimetinib arm was 2.8 months versus 1.5 months on the dacarbazine arm; hazard ratio (or HR) 0.62, [95% CI 0.47-0.80], p
Array plans to submit binimetinib to regulatory authorities for marketing approval in NRAS mutant melanoma during the first half of 2016.
ARRY closed at $4.42 and was trading below its 100-day moving average but above its 20-day moving average. Year-to-date (or YTD), ARRY has returned -6.
Sentiment: Strong Buy
I read about a special one time big dividend. Does anyone know when is it going to be issued please and how much? Thanks.
How many of you do you think ARRY is truly under valued?
FDX beat earning and revenue, stock dropped huge the 3 days in the row. LULU missed both earning and revenue plus guiding down, stock popped from $44 to $51. This market has really become a casino market nowadays. I understand from $50 to $44 is over killed, but to trade higher than before earning announcement is really strange.
Jeffrey Ubben's 13F portfolio decreased from $18.99B to $17.20B this quarter.
ValueAct Holdings decreased Adobe Systems while increasing Twenty First Century Fox during the quarter.
The top-three positions are Microsoft Corporation (19.37%), Valeant Pharmaceuticals (15.55%), and Halliburton (7.64%) and they add up to ~43% of the portfolio.
based on aggressive Q/E especially in Europe. Stocks in Europe and Asia are going to be shinning investment next year.
Europe is going to get very aggressive with its Q/E. Stock like POZN is going to pop to $10 in 2016.
I sold at $8.3 while my son continue to hold. The same strategy he has with RDN, I sold mine before $10 while he holds all the way over $20. I think NOK has potential chance to go to $10 next year.
My fiancé at IBM also join so as my son at Biomedical field. We all start tweeting and visiting Twitter much more than Facebook nowadays. Twitter provides much more value and knowledge than Facebook.
The money I spent on Groupon this year is at least triple than the last year. I really love the shopping list they present to my email daily. I am so busy that I just don't have the time to go on Amazon to browse and shop. Groupon makes my life so much easier especially during the holiday season. My children along with many of my friends have also decided to shop on Groupon and all are very pleased with their experience and purchases. I am not trying to pump the stock, but telling the true satisfaction of my experience shopping at Groupon. Great price and great customer service.